Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep929 | Pituitary - Clinical | ECE2016

Clinical management of pituitary teratomas and safety of rhgh replacement therapy: a case report

Chiloiro Sabrina , Giampietro Antonella , Bima Chiara , Bracaccia Maria Elena , De Marinis Laura

Teratomas comprise 0.5% of all intracranial tumors. 15 cases of sellar teratoma have been described in the last 24 years (yrs). A 29-yrs female pan-hypopituitaric patient (pt) was admitted to our Pituitary Unit. At 6-yrs age, for polyuria and growth delay, an endocrine evaluation revealed diabetes insipidus and hypopituitarism. Cranial contrasted-MRI (cc-MRI) showed pituitary stalk thickening and a low intensity suprasellar lesion. Histological examination (HE) was suggestive ...

ea0049ep991 | Pituitary - Clinical | ECE2017

Biochemical normalization in acromegaly after 79 months’ treatment with Pasireotide: case report

Bima Chiara , Chiloiro Sabrina , Iacovazzo Donato , Tartaglione Tommaso , Bracaccia Maria Elena , Giampietro Antonella , Bianchi Antonio , De Marinis Laura

Pasireotide, a multireceptor-targeted somatostatin analogue, was approved for the treatment of acromegaly, after being studied in two large, randomised, multi-center clinical trials. We reported the history of a 76 years old man affected by acromegaly, treated with Pasireotide long acting release (LAR) as first line therapy. Acromegaly was diagnosed in 2009, as the result of endocrinological investigation suggested by altered facial appearance and macroglossia. Hormonal assays...

ea0041ep928 | Pituitary - Clinical | ECE2016

Bone metabolism in acromegaly

Giampietro Antonella , Chiloiro Sabrina , Mormando Marilda , Bima Chiara , Bracaccia Maria Elena , Piacentini Serena , Tartaglione Linda , Iacovazzo Donato , Bianchi Antonio , De Marinis Laura

Aim: To evaluate calcium and bone metabolism in a monocentric series of acromegaly patients (pts), treated with pegvisomant (PEG) alone or in association to long acting somatostatine analogs.Patients and methods: All pts with at least 24 consecutive months PEG treatment (alone or in combination with SSA) were enrolled. All pts had been tested at least twice/year for biochemical acromegaly-disease evaluation and annually for calcium metabolism and for bon...